{"id":955958,"date":"2026-04-29T08:27:31","date_gmt":"2026-04-29T12:27:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biomericas-infoods-ibs-data-accepted-for-presentation-at-digestive-disease-week-2026\/"},"modified":"2026-04-29T08:27:31","modified_gmt":"2026-04-29T12:27:31","slug":"biomericas-infoods-ibs-data-accepted-for-presentation-at-digestive-disease-week-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biomericas-infoods-ibs-data-accepted-for-presentation-at-digestive-disease-week-2026\/","title":{"rendered":"Biomerica\u2019s inFoods\u00ae IBS Data Accepted for Presentation at Digestive Disease Week 2026"},"content":{"rendered":"

\nReal-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world\u2019s largest GI medical conference, May 2\u20135, 2026, in Chicago
\n<\/h2>\n
\n

IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) — Biomerica, Inc.<\/strong> (Nasdaq: BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an abstract evaluating the real-world clinical effectiveness of its inFoods\u00ae IBS<\/strong> diagnostic-guided therapy has been accepted for poster presentation at Digestive Disease Week\u00ae (DDW) 2026, to be held May 2\u20135, 2026, at McCormick Place in Chicago, Illinois.<\/p>\n

DDW is the world\u2019s largest gathering of physicians, researchers, and industry professionals in gastroenterology, hepatology, and related GI disciplines. Acceptance of this poster reflects the growing interest within the gastroenterology community in personalized, non-pharmacologic dietary management strategies for patients with irritable bowel syndrome (IBS).<\/p>\n\n\n
\n Novel IBS-specific Guided Elimination Diet Significantly Reduces Abdominal Symptoms in Individuals With IBS: A Real-world Experience<\/strong><\/p>\n

Authors: <\/strong>Bill Hirsch, MD (University of Michigan), William D. Chey, MD (University of Michigan), Anthony Lembo, MD (Clevland Clinic), Prashant Singh, MD (University of Michigan)<\/p>\n

Display Time: <\/strong>May 2, 2026 at 12:30 to 1:30 pm CT, McCormick Place, Chicago, IL<\/em><\/td>\n<\/tr>\n<\/table>\n

\n
The real-world study will be presented by investigators from Michigan Medicine (University of Michigan)<\/strong> and Cleveland Clinic<\/strong>. The study builds on findings from a multicenter, double-blinded, placebo-controlled trial of the inFoods\u00ae IBS test published in the June 2025 issue of Gastroenterology<\/em>. Per DDW embargo policy, study data will be made available beginning at 12:01 a.m. CDT on the day of presentation.<\/p>\n

\n ABOUT DIGESTIVE DISEASE WEEK\u00ae 2026<\/strong>\n <\/p>\n

Digestive Disease Week\u00ae (DDW) is the world\u2019s largest gathering of physicians, researchers, and industry professionals in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. DDW 2026 will be held May 2\u20135, 2026, in Chicago, Illinois. Additional information regarding DDW can be found at www.ddw.org<\/a>.<\/p>\n

\n ABOUT INFOODS\u00ae IBS<\/strong>\n <\/p>\n

inFoods\u00ae IBS is a diagnostic-guided therapy that identifies patient-specific food triggers responsible for symptoms such as abdominal pain, bloating, diarrhea, and constipation. Using a simple finger-stick blood sample, the test enables physicians to recommend targeted dietary changes tailored to the patient\u2019s immune response\u2014offering a non-pharmaceutical, precision-based approach to symptom relief.<\/p>\n

A multicenter, double-blinded sham-controlled trial on the inFoods\u00ae IBS test was published in the June 2025 issue of Gastroenterology<\/em>, a peer-reviewed GI journal. The study demonstrated statistically significant outcomes:<\/p>\n